SLC5A2 and hydrops fetalis: There have been several large clinical trials in the recent literature evaluating sodium-glucose cotransporter-2 (SGLT2-Is) inhibitors as a potential therapy for HF with reduced (and more recently preserved) ejection fraction (HFrEF, HFpEF).